BGM is a holding company that operates through contractual arrangements with its Chinese subsidiaries, primarily Gansu QLS. BGM operates two business lines: a legacy pharmaceutical business and a newer AI-powered insurtech division. In its pharmaceutical segment, BGM manufactures and sells oxytetracycline antibiotics, licorice-based medicines, crude heparin sodium, organic fertilizers, and sausage casings. BGM produces oxytetracycline as both tablets and active pharmaceutical ingredients for human and animal use. BGM derives heparin and sausage casing products from pig intestinal mucosa processed in Sichuan. BGM sells these products through a network of distributors and dealers across more than 20 Chinese provinces. The pharmaceutical business model relies on wholesale sales to distributors and corporate buyers, with profitability driven by volume and commodity pricing for raw materials like licorice root and pig intestines. Since late 2024, BGM has shifted its strategy toward technology through several acquisitions. Its AI business provides digital tools for insurance marketing, underwriting, and claims processing. These platforms use big data and AI agents to support insurance brokers and consumers in China. This technology segment is in its early stages as BGM attempts to diversify its revenue beyond its historical manufacturing base. The controlling shareholders maintain approximately 91.7% of voting power through a dual-class share structure.